SCHEMBL3320032

SCHEMBL3320032

O=C(CC12CC3CC(CC(C3)C1)C2)NCc1ccc(Cl)cc1

nearest known ligand 0.75

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.74
MEN1 O00255 2/20 0.74
SMN1; SMN2 Q16637 2/20 0.71
RAB9A P51151 1/20 0.68
P2RX7 Q99572 2/20 0.68
SPHK2 Q9NRA0 1/20 0.63
EPHX2 P34913 2/20 0.60
ALDH1A1 P00352 2/20 0.59
LMNA P02545 1/20 0.59
GAA P10253 1/20 0.59
MAPT P10636 1/20 0.59
ALOX12 P18054 1/20 0.59
HTT P42858 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
POLB P06746 1/20 0.56
HSD11B1 P28845 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3322052 0.86 KMT2A (0.74) KMT2AMEN1SMN1; SMN2RAB9AP2RX7
Adamantane SCHEMBL3322185 0.84 KMT2A (0.72) KMT2AMEN1SMN1; SMN2RAB9AP2RX7
SCHEMBL3318511 0.81 HPGD (0.75) KMT2AMEN1SMN1; SMN2SPHK2EPHX2
SCHEMBL2403209 0.78 HDAC3 (0.71) KMT2AMEN1SMN1; SMN2RAB9AEPHX2
SCHEMBL2407868 0.78 HDAC3 (0.71) KMT2AMEN1SMN1; SMN2RAB9AEPHX2
SCHEMBL2403178 0.77 KMT2A (0.65) KMT2AMEN1SMN1; SMN2RAB9AP2RX7
SCHEMBL14705903 0.77 ALDH1A1 (0.55) KMT2AMEN1SMN1; SMN2P2RX7ALDH1A1
SCHEMBL3322028 0.72 KMT2A (1.00) KMT2AMEN1SMN1; SMN2RAB9AP2RX7
SCHEMBL3327631 0.72 HSD11B1 (0.67) KMT2AMEN1SMN1; SMN2RAB9AP2RX7
SCHEMBL3323115 0.72 HSD11B1 (0.65) KMT2AMEN1RAB9AP2RX7EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120789-A1 Compound STERIX LIMITED (GB) 2010-05-13 US disclosed
US-20100120789-A1 Compound STERIX LIMITED (GB) 2010-05-13 US disclosed
US-20090042929-A1 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors STERIX LIMITED (GB) 2009-02-12 US disclosed
US-20090042929-A1 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors STERIX LIMITED (GB) 2009-02-12 US disclosed
EP-1861384-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS Sterix Limited (GB) 2007-12-05 EP disclosed
WO-2006100502-A1 11-BETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS STERIX LIMITED (GB) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042929-A1 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors HSD3B1, HSD3B2, HSD11B1 KMT2A 3083/4885MEN1 3474/4885SMN1; SMN2 4801/4885
US-20100120789-A1 Compound NR0B2, NR0B1, NR4A1 KMT2A 2533/4885MEN1 2608/4885SMN1; SMN2 4612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.